COSMO PHARMACEUTICALS NV (C43.DE) Stock Fundamental Analysis
FRA:C43 - Deutsche Boerse Ag - NL0011832936 - Common Stock - Currency: EUR
We assign a fundamental rating of 9 out of 10 to C43. C43 was compared to 50 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making C43 a very profitable company, without any liquidiy or solvency issues. C43 is evaluated to be cheap and growing strongly. This does not happen too often! C43 also has an excellent dividend rating. These ratings could make C43 a good candidate for value and dividend and growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year C43 was profitable.
C43 had a positive operating cash flow in the past year.
In multiple years C43 reported negative net income over the last 5 years.
Each year in the past 5 years C43 had a positive operating cash flow.
1.2 Ratios
C43 has a Return On Assets of 20.60%. This is amongst the best in the industry. C43 outperforms 94.00% of its industry peers.
C43 has a better Return On Equity (26.74%) than 78.00% of its industry peers.
The Return On Invested Capital of C43 (21.60%) is better than 90.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| ROIC | 21.6% |
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 49.94%, C43 belongs to the top of the industry, outperforming 98.00% of the companies in the same industry.
In the last couple of years the Profit Margin of C43 has grown nicely.
C43's Operating Margin of 55.81% is amongst the best of the industry. C43 outperforms 100.00% of its industry peers.
In the last couple of years the Operating Margin of C43 has grown nicely.
With an excellent Gross Margin value of 83.00%, C43 belongs to the best of the industry, outperforming 86.00% of the companies in the same industry.
C43's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 55.81% | ||
| PM (TTM) | 49.94% | ||
| GM | 83% |
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so C43 is creating value.
Compared to 1 year ago, C43 has less shares outstanding
The number of shares outstanding for C43 has been increased compared to 5 years ago.
Compared to 1 year ago, C43 has an improved debt to assets ratio.
2.2 Solvency
C43 has an Altman-Z score of 5.80. This indicates that C43 is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of C43 (5.80) is better than 90.00% of its industry peers.
The Debt to FCF ratio of C43 is 0.01, which is an excellent value as it means it would take C43, only 0.01 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of C43 (0.01) is better than 98.00% of its industry peers.
C43 has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
C43's Debt to Equity ratio of 0.00 is amongst the best of the industry. C43 outperforms 94.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Altman-Z | 5.8 |
ROIC/WACC2.81
WACC7.68%
2.3 Liquidity
A Current Ratio of 4.19 indicates that C43 has no problem at all paying its short term obligations.
C43's Current ratio of 4.19 is amongst the best of the industry. C43 outperforms 96.00% of its industry peers.
C43 has a Quick Ratio of 3.91. This indicates that C43 is financially healthy and has no problem in meeting its short term obligations.
C43 has a better Quick ratio (3.91) than 96.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.19 | ||
| Quick Ratio | 3.91 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 1315.29% over the past year.
C43 shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 85.20% yearly.
Looking at the last year, C43 shows a very strong growth in Revenue. The Revenue has grown by 187.55%.
Measured over the past years, C43 shows a very strong growth in Revenue. The Revenue has been growing by 33.68% on average per year.
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
3.2 Future
C43 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.02% yearly.
C43 is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.67% yearly.
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 5.98, the valuation of C43 can be described as very cheap.
Based on the Price/Earnings ratio, C43 is valued cheaper than 92.00% of the companies in the same industry.
C43's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.12.
The Price/Forward Earnings ratio is 8.09, which indicates a very decent valuation of C43.
Based on the Price/Forward Earnings ratio, C43 is valued cheaply inside the industry as 84.00% of the companies are valued more expensively.
C43 is valuated cheaply when we compare the Price/Forward Earnings ratio to 20.42, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.98 | ||
| Fwd PE | 8.09 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, C43 is valued cheaper than 96.00% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of C43 indicates a rather cheap valuation: C43 is cheaper than 92.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.46 | ||
| EV/EBITDA | 3.83 |
4.3 Compensation for Growth
C43 has an outstanding profitability rating, which may justify a higher PE ratio.
C43's earnings are expected to decrease with -27.68% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.04%, C43 is a good candidate for dividend investing.
The stock price of C43 dropped by -28.24% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
C43's Dividend Yield is a higher than the industry average which is at 3.06.
Compared to an average S&P500 Dividend Yield of 2.44, C43 pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.04% |
5.2 History
The dividend of C43 is nicely growing with an annual growth rate of 7.41%!
Dividend Growth(5Y)7.41%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
C43 pays out 24.09% of its income as dividend. This is a sustainable payout ratio.
C43's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP24.09%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
FRA:C43 (4/29/2025, 7:00:00 PM)
48.8
-1.2 (-2.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners12.98%
Inst Owner ChangeN/A
Ins Owners38.78%
Ins Owner ChangeN/A
Market Cap855.95M
Analysts84
Price Target104.72 (114.59%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.04% |
Yearly Dividend2
Dividend Growth(5Y)7.41%
DP24.09%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.05%
PT rev (3m)1.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)2.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-13.87%
Revenue NY rev (3m)-12.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.98 | ||
| Fwd PE | 8.09 | ||
| P/S | 3.21 | ||
| P/FCF | 5.46 | ||
| P/OCF | 5.27 | ||
| P/B | 1.72 | ||
| P/tB | 6.01 | ||
| EV/EBITDA | 3.83 |
EPS(TTM)8.16
EY16.72%
EPS(NY)6.03
Fwd EY12.36%
FCF(TTM)8.94
FCFY18.31%
OCF(TTM)9.26
OCFY18.97%
SpS15.21
BVpS28.41
TBVpS8.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| ROCE | 24.88% | ||
| ROIC | 21.6% | ||
| ROICexc | 28.38% | ||
| ROICexgc | 129.8% | ||
| OM | 55.81% | ||
| PM (TTM) | 49.94% | ||
| GM | 83% | ||
| FCFM | 58.76% |
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y181.33%
ROICexcg growth 5YN/A
ROICexc growth 3Y154.84%
ROICexc growth 5YN/A
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 46.02% | ||
| Cap/Sales | 2.12% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 100.77% | ||
| Profit Quality | 117.65% | ||
| Current Ratio | 4.19 | ||
| Quick Ratio | 3.91 | ||
| Altman-Z | 5.8 |
F-Score8
WACC7.68%
ROIC/WACC2.81
Cap/Depr(3y)45.29%
Cap/Depr(5y)77.05%
Cap/Sales(3y)4.67%
Cap/Sales(5y)8.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
EBIT growth 1Y8040.37%
EBIT growth 3Y137.59%
EBIT growth 5YN/A
EBIT Next Year-33.52%
EBIT Next 3Y-14.79%
EBIT Next 5Y28.59%
FCF growth 1Y756.04%
FCF growth 3Y236.69%
FCF growth 5YN/A
OCF growth 1Y615.22%
OCF growth 3Y134.4%
OCF growth 5YN/A